Due to the increased accumulation of docetaxel (DTX) in both tumor tissue and tumor vasculature, Flk-1 mAb-targeted DTX-loaded NLC showed better antitumor efficacy than non-targeted NLC and Duopafei® (free DTX) against three human (HepG2, A549, and B16) cell lines and one malignant melanoma mouse model (dosage of 20 mg/kg). This evidence concerns the gene KDR and neoplasm.